Kjell E. Öberg

Kjell E. Öberg's AcademicInfluence.com Rankings

Kjell E. Öberg

Philosophy

#6324

World Rank

#9345

Historical Rank

Logic

#3502

World Rank

#4675

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Kjell E. Öberg's Degrees

PhD Medical Sciences Uppsala University
Doctorate Medicine Uppsala University

Why Is Kjell E. Öberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kjell E. Öberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors (2017) (1823)
Everolimus for advanced pancreatic neuroendocrine tumors. (2011) (1062)
Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma (1988) (990)
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary (2011) (789)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011) (768)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site (2016) (758)
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (466)
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors (2007) (434)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (373)
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum (2016) (352)
Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumour (1990) (350)
Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution (2008) (349)
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours (2004) (323)
Tumor Markers in Neuroendocrine Tumors (2000) (288)
Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases (2002) (284)
Malignant Carcinoid Tumors An Analysis of 103 Patients with Regard to Tumor Localization, Hormone Production, and Survival (1987) (283)
Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography (2005) (259)
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma (2007) (256)
Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy (2011) (246)
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. (2017) (239)
Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma (2007) (239)
Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors (1998) (234)
Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center (2012) (206)
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. (2012) (204)
Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. (2011) (203)
ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas) (2016) (192)
Current knowledge on diagnosis and staging of neuroendocrine tumors (2011) (190)
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus) (2010) (179)
Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (172)
Medical treatment and long‐term survival in a prospective study of 84 patients with endocrine pancreatic tumors (1990) (163)
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues (2015) (161)
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas (2009) (147)
Preoperative Diagnosis and Surgical Management of Neuroendocrine Gastroenteropancreatic Tumors: General Recommendations by a Consensus Workshop* (1998) (146)
Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients (1990) (131)
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) (2004) (121)
Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids (1998) (116)
Surgical treatment of mid-gut carcinoid tumors (1990) (116)
Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors (2013) (116)
Interferon in the Management of Neuroendocrine GEP-Tumors (2000) (116)
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part I—General Overview (2004) (115)
TREATMENT OF MALIGNANT ENDOCRINE PANCREATIC TUMOURS WITH HUMAN LEUCOCYTE INTERFERON (1986) (113)
PET in the Diagnosis of Neuroendocrine Tumors (2004) (111)
Surgery for Asymptomatic Pancreatic Lesion in Multiple Endocrine Neoplasia Type I (1996) (110)
The Role of PET in Localization of Neuroendocrine and Adrenocortical Tumors (2002) (110)
Implications for Clinical Practice and Trial Design (2012) (109)
Octreoscan in patients with bronchial carcinoid tumours (2003) (108)
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours (2001) (108)
Imaging of Neuroendocrine Tumors. (2016) (104)
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs (2016) (103)
Pancreatic Endocrine Tumors (2010) (100)
Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years (2007) (99)
AUTOIMMUNE THYROID DISEASE IN INTERFERON-TREATED PATIENTS (1985) (97)
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. (2017) (93)
Progression of Metastases and Symptom Improvement from Laparotomy in Midgut Carcinoid Tumors (1996) (90)
Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment (1999) (90)
Neuroendocrine tumours of the pancreas (2000) (87)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
Autoimmune Phenomena in Patients with Malignant Carcinoid Tumors During Interferon-α Treatment (1991) (86)
The role of interferons in the management of carcinoid tumours (1991) (83)
Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography (2005) (83)
Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin (2007) (83)
Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs (2002) (81)
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part II—Specific NE Tumour Types (2004) (80)
Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes (1992) (77)
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (2010) (77)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy (2008) (77)
The genetics of neuroendocrine tumors. (2013) (73)
Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids (2013) (72)
Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival (2017) (71)
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. (2016) (71)
Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors (2008) (70)
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. (2021) (69)
ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors (2010) (69)
A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B (2004) (67)
ENETS Consensus Guidelines for the Management of Brain, Cardiac and Ovarian Metastases from Neuroendocrine Tumors (2010) (66)
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. (2020) (66)
NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate. (2016) (65)
Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors (2003) (63)
Gastrointestinal neuroendocrine tumors. (2010) (62)
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (2017) (62)
Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment (1992) (59)
Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors (2010) (58)
Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer (2004) (58)
Neuroendocrine gastrointestinal tumours (1996) (57)
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020) (57)
Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability (2010) (57)
Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. (2013) (55)
Future Aspects of Somatostatin- Receptor-Mediated Therapy (2004) (54)
Targeted disruption of the mouse phospholipase C β3 gene results in early embryonic lethality (1998) (54)
Limited Tumor Involvement Found at Multiple Endocrine Neoplasia Type I Pancreatic Exploration: Can It Be Predicted by Preoperative Tumor Localization? (1998) (53)
Management of functional neuroendocrine tumors of the pancreas. (2018) (51)
Advances in chemotherapy and biotherapy of endocrine tumors (1998) (49)
The management of neuroendocrine tumours: current and future medical therapy options. (2012) (49)
Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. (2014) (48)
6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial (2015) (47)
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs) (2012) (46)
Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms (2016) (45)
Somatostatin analogs for the treatment of neuroendocrine tumors (2011) (44)
Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment (2002) (44)
Diagnosis and treatment of carcinoid tumors (2003) (43)
The Use of Chemotherapy in the Management of Neuroendocrine Tumors (1993) (43)
A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A (2004) (42)
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. (2017) (42)
A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy (2007) (42)
Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors (2012) (42)
Parathyroid surgery in the multiple endocrine neoplasia type I syndrome: Choice of surgical procedure (1986) (42)
The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells (2012) (41)
Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role (2015) (41)
Biomarkers and Molecular Imaging in Gastroenteropancreatic Neuroendocrine Tumors (2011) (41)
177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial (2016) (40)
Operative tumour yield obviates preoperative pancreatic tumour localization in multiple endocrine neoplasia type 1 (1995) (40)
Characterization of anti‐interferon‐α antibodies appearing during recombinant interferon‐α2a treatment (1992) (39)
Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids. (2013) (38)
Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs (2015) (38)
PPomas and Nonfunctioning Endocrine Pancreatic Tumors: Clinical Presentation, Diagnosis, and Advances in Management (1994) (37)
Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors? (2012) (37)
Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome – An International Consensus Statement (2020) (36)
Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours (2011) (36)
Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors (1984) (35)
Established Clinical Use of Octreotide and Lanreotide in Oncology (2001) (35)
Endocrine tumors of the gastrointestinal tract: systemic treatment. (1994) (35)
The Clinical Use of Interferons in the Management of Neuroendocrine Gastroenteropancreatic Tumors (1994) (35)
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial (2015) (34)
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue (2009) (34)
Biotherapies for GEP-NETs. (2012) (33)
Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors) (2009) (33)
A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs (2013) (32)
Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors (2007) (31)
Angiography, Computed Tomography, Magnetic Resonance Imaging and Ultrasonography in Detection of Liver Metastases from Endocrine Gastrointestinal Tumours (1987) (31)
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. (2020) (31)
Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells (2011) (31)
Gene expression in midgut carcinoid tumors: Potential targets for immunotherapy (2005) (30)
Quality of life in patients with multiple endocrine neoplasia type 1 (MEN1) (2004) (30)
The action of interferon alpha on human carcinoid tumours. (1992) (30)
Management of neuroendocrine tumours. (2004) (30)
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. (2019) (30)
Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges (2014) (29)
Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study (2016) (29)
NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results. (2016) (29)
Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare? (2014) (29)
The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors (1997) (29)
Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells (2004) (27)
Carcinoid tumors, carcinoid syndrome and related disorders (2007) (27)
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients (2008) (27)
SUCCESSFUL TREATMENT OF THERAPY-RESISTANT PANCREATIC CHOLERA WITH HUMAN LEUCOCYTE INTERFERON (1985) (27)
Neuroendocrine Neoplasms (2011) (26)
lnterferon-α versus Somatostatin or the Combination of Both in Gastro-Enteropancreatic Tumours (1996) (26)
Treatment of hormone‐producing adrenocortical cancer with o,p'DDD and streptozocin (1987) (26)
Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues (2007) (26)
Regression of a Large Malignant Gastrinoma on Treatment with Sandostatin LAR®: A Case Report (2008) (26)
Experience with multiple endocrine neoplasia type 1 screening (1995) (25)
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (24)
Treatment of the Carcinoid Syndrome with SMS 201-995, a Somatostatin Analogue (1986) (24)
Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines (2009) (24)
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms (2014) (23)
Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut (1983) (23)
37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial) (2015) (23)
REDUCTION OF GASTRIC HYPERSECRETION IN ZOLLINGER-ELLISON SYNDROME WITH OMEPRAZOLE (1983) (23)
Somatostatin analog octreotide LAR® in gastro–entero–pancreatic tumors (2009) (23)
Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours (1995) (21)
Expression of Growth Factors and Their Receptors in Neuroendocrine Gut and Pancreatic Tumors, and Prognostic Factors for Survival (1994) (21)
Autoantibodies to epithelial cells in patients on long‐term therapy with leucocyte‐derived interferon‐alpha (IFN‐α) (1990) (20)
Treatment of neuroendocrine tumors (1994) (19)
Silver stains for identification of neuroendocrine cells. A study of the chemical background (1990) (19)
Midgut Carcinoid Tumours (1995) (19)
Gene Transfer of Vasostatin, a Calreticulin Fragment, into Neuroendocrine Tumor Cells Results in Enhanced Malignant Behavior (2006) (18)
Rectal neuroendocrine tumors : Diagnosis and treatment (2007) (18)
Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia. (2012) (18)
Molecular imaging of neuroendocrine tumors (2008) (18)
Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment (2005) (17)
Selective effects of somatostatin analogs on human drug‐metabolizing enzymes (1998) (17)
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. (2018) (17)
Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract. (1994) (17)
State of the art and future prospects in the management of neuroendocrine tumors. (2000) (16)
Expression of Tyrosine Kinase Receptors in Lung Carcinoids (2006) (16)
Decreased survival in patients with CD44‐negative typical bronchial carcinoid tumors (1999) (16)
Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations (2013) (15)
PET-Guided Surgery — High Correlation between Positron Emission Tomography with 11C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours (2012) (15)
Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches (2012) (15)
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis (2015) (15)
Nuclear DNA in intestinal carcinoid tumors. A study before and after cytotoxin (streptozotocin and 5‐Fluorouracil) treatment (1985) (15)
Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR (2005) (15)
Neuroendocrine gastrointestinal tumours - a condensed overview (1999) (14)
Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science (2013) (14)
Neuroendocrine gastro-enteropancreatic tumors – from eminence based to evidence-based medicine – A Scandinavian view (2015) (14)
Diagnosis of Endocrine Gastrointestinal Tumours (1981) (14)
Interferon Therapy of Malignant Endocrine Pancreatic Tumors1 (1994) (14)
Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies (2006) (14)
Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors (2013) (14)
The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018. (2018) (13)
RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe. (2012) (13)
Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift (2018) (13)
PROGNOSTIC AND PREDICTIVE VALUE OF CHROMOGRANIN A AND NEURON-SPECIFIC ENOLASE IN PATIENTS (PTS) WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH EVEROLIMUS (2010) (13)
Management of Neuroendocrine Tumors: A Meeting of Experts from Latin America (2008) (13)
Catecholamine‐Secreting Metastatic Carcinoid as Differential Diagnosis in Pheochromocytoma (2006) (12)
Roles of miR-196a on gene regulation of neuroendocrine tumor cells (2015) (12)
Expression and Function of Vinculin in Neuroendocrine Tumors (2007) (12)
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs (2002) (12)
The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR (2007) (12)
Neuroendocrine tumors: recent progress in diagnosis and treatment. (2011) (12)
Meal-stimulated and atropine-inhibited secretion of pancreatic polypeptide in healthy subjects, members of MEA I families and patients with malignant endocrine tumours of the gastrointestinal tract (1983) (12)
Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow upp of carcinoid tumors (1998) (11)
Erratum: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors (Neuroendocrinology (2004) 80 (394-424)) (2005) (11)
Gastrointestinal Carcinoid Tumors (Gastrointestinal Neuroendocrine Tumors) and the Carcinoid Syndrome (2010) (11)
Positron‐Emission Tomography as a Radiological Technique in Neuroendocrine Gastrointestinal Tumors (1994) (10)
Increased intestinal non‐substance P tachykinin concentrations in malignant midgut carcinoid disease (1999) (10)
In vivo demonstration of enzyme activity in endocrine pancreatic tumors - decarboxylation of 11C-dopamine. (1996) (10)
Preoperative Localization of Endocrine Pancreatic Tumours by Intra-Arterial Dynamic Computed Tomography (1990) (10)
1. Neuroendocrine Tumors (NETs): Historical Overview and Epidemiology (2010) (10)
Autoimmunity and Antibodies to Interferons in Patients with Carcinoid Tumors—Clinical Consequences (1994) (10)
Candidate genes for multiple endocrine neoplasia type 1 (1995) (10)
A century of advances in neuroendocrine tumor biology and treatment : A tribute to Siegried Oberndorfer (2007) (10)
Ramsete : a single-arm, multicenter, single-stage phase ii trial of rad001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in europe: analysis by tumor origin (2012) (10)
Medical Therapy of Gastrointestinal Neuroendocrine Tumors (2017) (10)
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. (2019) (9)
Molecular Genomic Blood Biomarkers for Neuroendocrine Tumors: The Long and Winding Road from Berzelius and Bence Jones to a Neuroendocrine Destination (2020) (9)
Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers (2018) (9)
Electron-microscopical immunocytochemical study of a pancreatic islet amyloid polypeptidoma (1991) (9)
The Ultimate Biochemical Diagnosis of Gastro-Enteropancreatic Tumours (1996) (9)
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE (2021) (9)
Management of neuroendocrine tumors: current and future therapies (2011) (8)
NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE. (2016) (8)
Suppression of the neoplastic phenotype by transfection of phospholipase C β 3 to neuroendocrine tumor cells (1999) (8)
Omeprazole inhibits growth of cancer cell line of colonic origin (1995) (8)
A chromogranin peptide is co-stored with insulin in the human pancreatic islet B-cell granules (1992) (8)
Dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis: a randomized controlled study (2019) (7)
Antiserum directed against chromogranin A and B (CAB) is a useful marker for peptide hormone-producing endocrine cells and tumors (1992) (7)
Clinical and biochemical effects in vivo of monoclonal antitumor antibody in verner‐morrison's syndrome (1994) (7)
Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors (2009) (7)
In situ hybridization study of chromogranin A and B mRNA in carcinoid tumors (2004) (6)
Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy (2020) (6)
ENETS consensus guidelines for synoptic reporting of radiology studies. (2021) (6)
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours (2021) (6)
NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis (2016) (6)
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma (2020) (6)
Somatostatin induces rapid contraction of neuroendocrine cells (2007) (6)
Peptide hormone markers in endocrine gastrointestinal tumours (1981) (5)
Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period (2016) (5)
Efficient Human Interferon-α Gene Transfer to Neuroendocrine Tumor Cells with Long-Term and Stable Expression (2006) (5)
WDHA syndrome caused by a ganglioneuroblastoma producing vasoactive intestinal polypeptide and neuropeptide Y (1986) (5)
Cardiac Imaging in Carcinoid Heart Disease. (2021) (5)
Lung and Thymic Neuroendocrine Tumors (2009) (5)
Multiple endocrine neoplasia 1 (1995) (5)
Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201–995 (1987) (5)
Molecular cloning and characterization of a cDNA encoding mouse phospholipase C-β3 (1998) (5)
Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR (2010) (5)
Neuroendocrine Gastroenteropancreatic Tumours – Current Views on Diagnosis and Treatment (2005) (5)
MHC class I and II antigen expression and interferon α treatment of human midgut carcinoid tumors (1994) (5)
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome (2017) (5)
Gastrin-releasing-peptide in neuroendorine tumours (2006) (4)
Biological Aspects of Neuroendocrine Gastro-Enteropancreatic Tumours (1996) (4)
Fetal alcohol spectrum disorder: complexity from comorbidity (2016) (4)
Neuroendocrine tumors and CUP (2012) (4)
Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors (2018) (4)
Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors (2013) (4)
Selective internal radiation therapy in patients with carcinoid liver metastases (2008) (4)
Carcinoid and flushing syndromes (2001) (4)
Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®) (2010) (4)
Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study (2021) (4)
Molecular imaging in diagnosis of neuroendocrine tumours. (2006) (3)
Clinical presentation, diagnosis, and advances in the management of PPomas and non-functioning endocrine pancreatic tumors. (1995) (3)
Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial (2017) (3)
Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome (2016) (3)
Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial (2016) (3)
Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patients—The ENETS registry. (2018) (3)
PET for clinical diagnosis and research in neuroendocrine tumors (2003) (3)
Carcinoid tumors - current considerations (2007) (3)
Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) versus Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET) : Phase III RADIANT-3 Results (2011) (3)
Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews (2016) (3)
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (3)
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment (2021) (3)
Universal everolimus for malignant neuroendocrine tumours? (2016) (3)
Interferon therapy of malignant endocrine pancreatic tumors. In: Endocrine tumors of the pancreas - Recent advances (1995) (3)
Neoplasms of the Neuroendocrine Pancreas: Insulinoma (2017) (3)
THE PANCREAS AND GUT (1989) (3)
12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 11-13, 2015, Barcelona, Spain: Abstracts (2015) (3)
Expert Review of Endocrinology & Metabolism: major coverage of the advances in an expanding field (2006) (2)
Interferon Treatment of Neuroendocrine Gut and Pancreatic Tumors (1990) (2)
Advances in Neuroendocrine Tumor Management (2011) (2)
Everolimus plus octreotide long-acting release (LAR) for the treatment of advanced neuroendocrine tumors (NET) associated with carcinoid syndrome (RADIANT-2) : Updated overall survival results (2013) (2)
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. (2017) (2)
Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis (2015) (2)
Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET) : A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data (2014) (2)
Does modern treatment of early rheumatoid arthritis reduce the need for intra-articular glucocorticoids? (2013) (2)
Survival and Clinical Characteristics in 284 Patients with Malignant Midgut Carcinoid Tumors (2007) (2)
First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial. (2021) (2)
Interferon Therapy of Neuroendocrine Tumours (1997) (2)
The Role of Interferons in the Treatment of Solid Tumors (1993) (2)
Screening for multiple endocrine neoplasia type 1 syndrome (1993) (2)
Effect of Interferon on T1 Relaxation Times of Liver Metastases from Endocrine Gastrointestinal Tumours (1988) (2)
Tumor markers in neuroendocrine gastrointestinal tumors (2004) (2)
Somatostatin receptor scinti-graphy-recent advances concerning imaging of endocrine pancreatic tumors (1993) (2)
Whole-body 11C-5-HTP-PET as a general imaging technique for detection of Neuroendocrine tumors - a comparison with somatostatin receptor scintigraphy and computed tomography (2003) (2)
CHAPTER 44 – Neuroendocrine Gastrointestinal and Lung Tumors (Carcinoid Tumors), Carcinoid Syndrome, and Related Disorders (2011) (2)
Chemical characterization and strategic selection of BFRs for PBT assessment (2004) (1)
Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
Instructions for the preparation of gene mapping reports (1995) (1)
Olfactory receptor 51E1 is a potential novel tissue biomarker for the diagnosis and prognosis of small intestine neuroendocrine tumors (2012) (1)
Advances in Pulmonary Neuroendocrine Tumor Management (2013) (1)
Role of somatostatin analogues in oncology : European Neuroendocrine Tumour Network (ENET), February 24-27, 2000, Innsbruck, Austria/ guest editor, Kjell Oberg (2000) (1)
Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management : Results from the First Global NET Patient (pt) Survey - A Collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals (2015) (1)
NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors (2017) (1)
The Role of Interferons in Neuroendocrine Tumours and Aspects of Mechanisms of Action (1991) (1)
Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with Sandostatin (1989) (1)
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors (2018) (1)
6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2) (2011) (1)
Treatment of malignant carcinoid tumors with recombinant interferon alpha-2 (Intron-A) (1987) (1)
Advances in diagnosing and treating adrenal tumors. (1990) (1)
Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy (2013) (1)
Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) (2011) (1)
Treatment of neuroendocrine tumours of the gastrointestinal tract (2004) (1)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 1 of 4) (1992) (1)
HCG‐α and HCG‐β Subunits as Tumour Markers during Therapy in a Case with So‐Called “Non‐Functioning” Islet Cell Tumour (2009) (1)
Monoclonal antibodies raised against mid-gut carcinoid tumor cells (1990) (1)
TEMOZOLOMIDE IN PATIENTS WITH METASTATIC BRONCHIAL CARCINOIDS (2011) (1)
Ultrasound-Guided Biopsies of Neuroendocrine Metastases (1993) (1)
Interferon Treatment of Neuro-Endocrine Tumors of Pancreas and Gut (1988) (1)
Circulating microRNA detection in small intestinal neuroendocrine tumor patients treated with somatostatin analogs (2014) (1)
Consensus Report, 1987 (1987) (1)
Genetics of Multiple Endocrine Neoplasia Type 1 (1994) (1)
Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors? (2018) (1)
Treatment strategies in neuroendocrine tumours (2011) (1)
Everolimus plus Octreotide LAR versus Placebo plus Octreotide LAR in Patients with Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2) (2011) (1)
Treatment of high-grade neuroendocrine tumors beyond platinum/etoposide (2014) (1)
A Multinational Pilot Study on Patients’ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires (2022) (1)
Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. (2017) (1)
Ectopic ACTH syndrome. An underdiagnosed condition (1997) (1)
The role of radiopharmaceuticals in diagnosis of neuroendocrine tumors (2006) (0)
ACTH producing tumour with Cushing syndrome (2017) (0)
DRAFT: RAMSETE trial of everolimus (RAD001) in the treatment of silent (nonfunctioning) advanced neuroendocrine tumors. (2010) (0)
Contents Vol. 91, 2010 (2010) (0)
FRI-14 Modern systemic therapy of neuroendocrine tumors in 2013 (2013) (0)
Histopathogenesis of mid-gut carcinoids (1987) (0)
Functional Role of miR-196a in Neuroendocrine Tumor Cells (2015) (0)
Somatostatin Analogue Therapy of Neuro-Endocrine Gastro-Entero Pancreatic Tumors (2004) (0)
Summation Session Section II : Neuroendocrine cell biology (2007) (0)
Neuroendocrine tumors: Preface (2010) (0)
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. (2019) (0)
Editorial - Neuroendocrine tumors A growing cancer field (2011) (0)
Chemotherapy and biotherapy in neuroendocrine tumors (1993) (0)
Neuroendocrine tumors A growing cancer field (2011) (0)
A perspective on the treatment of gastro-entero pancreatic tumors (GEP). Octreotide: The Next Decade (1999) (0)
Faculty Opinions recommendation of Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011) (0)
Subject Index Vol. 91, 2010 (2010) (0)
Faculty Opinions recommendation of Chromogranin A: is it a useful marker of neuroendocrine tumors? (2007) (0)
The role of the somatostatin analogues (2004) (0)
Management of metastatic neuroendocrine tumors : Recent advances, Changing trends in the management of NET (2010) (0)
Chapter 43 – Neuroendocrine Gastrointestinal and Lung Tumors (Carcinoid Tumors), the Carcinoid Syndrome, and Related Disorders (2016) (0)
Chapter 151 – Carcinoid Syndrome (2016) (0)
Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl (2017) (0)
Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges (2014) (0)
Title Page / Contents (2000) (0)
Clinical management of neuroendocrine GEP-tumors - Current concepts and future directions (2007) (0)
Duplex Doppler ultrasound in carcinoid metastases (1991) (0)
Contents Vol. 82, 2005 (2006) (0)
Malignant carcinoid tumors — long-term treatment with SMS 201–995 (1987) (0)
SAT0250 The dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis – a randomized controlled study (2018) (0)
Subject Index Vol. 80, 2004 (2005) (0)
Negative Lung Carcinoids 2 (2013) (0)
363 Production of PP and HCG-a in lung-carcinoids with the carcinoid syndrome (1983) (0)
548 PET for visualization of C-11-L-DOPA uptake and decarboxylation in endocrine pancreas cancer (1995) (0)
Neuroendocrine tumors : New perspection in their therapy (2000) (0)
Treatment upon Metastatic Pancreatic Nets: Does Chemotherapy Still Play a Role in the Area of Targeting Treatment? (2012) (0)
Dr. Yao and colleagues reply (2011) (0)
The secretion of PP in MEA-I members, combined stimulatory and inhibitory test (1983) (0)
Function of IFN-α gene products in neuroendocrine tumors. (2007) (0)
Receptor Ligands : Somatostatin analogs (2009) (0)
Subject Index Vol. 82, 2005 (2006) (0)
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. Authors' reply (2004) (0)
How does PROMID change the treatment landscape of NET (2010) (0)
MicroRNA Expression in Serum of Small Intestine Neuroendocrine Tumor Patients and miR-196a Biological Function in Neuroendocrine Tumor Cells (2014) (0)
Workshop 2: Neuroendocrine tumors: Genetics, tumor biology and treatment (2009) (0)
Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors (2014) (0)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 3 of 4) (1992) (0)
Algorithm for management of bronchopulmonary neuroendocrine tumors (2013) (0)
Therapy evaluation of neuroendocrine liver metastases with contrast-enhanced MRI (2004) (0)
Management of Advanced Small Intestinal Neuroendocrine Tumors (2011) (0)
Early detection of endocrine pancreatic tumors in men-1 — a clinical benefit of a standardized meal stimulatory test (1987) (0)
Which therapy for which patient (2011) (0)
PET imaging in endocrine tumors. In: Diagnostic Nuclear Medicine (1995) (0)
Microarray Immunoassay Development to Specifically Detect Autoantibodies in Small Intestine Neuroendocrine Tumor (SI-NET) Patients (2013) (0)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 2 of 4) (1992) (0)
Weight change associated with telotristat ethyl in the treatment of carcinoid syndrome (2017) (0)
Association of neuroendocrine gastroenteropancreatic tumor disease with multiple endocrine neoplasia type I (1995) (0)
Best Practice & Research Clinical Gastroenterology (2013) (0)
Therapy for Metastatic Disease: Bronchi (2018) (0)
Recent Advances in Diagnosis and Treatment OF Neuroendocrine Gut and Pancreatic Tumors: A meeting held at Kebnekaise, Sweden, June 13-16, 1990 (1991) (0)
miR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease (2016) (0)
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. (2019) (0)
Neuroendocrine gut and pancreatic tumors (apudomas). (1995) (0)
Contents Vol. 101, 2015 (2015) (0)
Neuroendocrine Gastroenteropancreatic Tumors—Recent Update on Diagnosis and Treatment (2006) (0)
Transmembrane protein tyrosine phosphatase IA-2 (ICA 512) is expressed in human midgut carcinoids but is not detectable in normal EC cells. (2000) (0)
Neoplasms of the Neuroendocrine Pancreas: Somatostatinoma (2017) (0)
B12Global MicroRNA Profiling of Small Intestine Neuroendocrine Tumors (SI-NETs) and Establishment of a Method to Study Serum MicroRNA Expression From the Same Tumors (2013) (0)
Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0 (2020) (0)
Multigene liquid biopsy (NETest) is diagnostic of pancreatic and small bowel neuroendocrine tumours and correlates with imaging (2020) (0)
Neoplastic disorders of the adrenal glands (2006) (0)
Faculty Opinions recommendation of Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. (2008) (0)
IN-111-OCTREOTIDE SCINTIGRAPHY IN MALIGNANT CARCINOID TUMOURS (1994) (0)
Thyroid Autoimmunity Induced by Interferon Therapy (1991) (0)
Unblocking Bottlenecks: Gastrointestinal and Lung Neuroendocrine Tumors Early Detection (2013) (0)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 4 of 4) (1992) (0)
patients with advanced neuroendocrine tumors refractory or resistant to (2012) (0)
The somatostatin analogue PTR-3173, a backbone cyclic peptide with effect on growth hormone but not insulin secretion (2000) (0)
Expression of somatostatin receptor subtypes 1-5 in malignant endocrine pancreatic tumors (2002) (0)
Predicting responses to interferon (1990) (0)
Circulating Biomarkers in Neuroendocrine Tumours (2015) (0)
ENETS Newsletter Summer/Fall 2013 (2013) (0)
Roles of somatostatin analogues in oncology (2000) (0)
Societies and Guidelines for Neuroendocrine Tumors (2015) (0)
Editorial (2000) (0)
Chapter 6, Diagnostic pathways : (2010) (0)
Chairperson's Introduction (2009) (0)
Expression of c-Kit, phospho-c-kit, PDGFRβ and absence of c-Kit mutation in exon 11 in adrenocortical cancer (2004) (0)
Chromogranin a — a marker for neuroendocrine tumors (1987) (0)
The Carcinoid Syndrome (1973) (0)
Business Briefing : European oncology review (2005) (0)
Rationale for Combining mTOR with other Targeted Agents in the Treatment of Neuroendocrine Tumors (2010) (0)
Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data (2015) (0)
Faculty Opinions recommendation of Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. (2011) (0)
PREDICTING RESPONSES TO INTERFERON. REPLY (1990) (0)
ENETS News Letter (2015) (0)
Contents Vol. 100, 2014 (2015) (0)
Chromogranin A and B in Hirschsprung's disease (1993) (0)
Contents Vol. 80, 2004 (2005) (0)
Small intestine and carcinoid tumours. (2002) (0)
Section Introduction: Emergent Management of Neuroendocrine Tumors (2014) (0)
Nordic and North American neuro endocrine tumor management : A clinical and scientific synopsis (2008) (0)
Chromogranin in endocrine cells and carcinoids of small intestine (1987) (0)
Neuroendocr ine Gas t roenteropancreat i c Tumors — Recent Update on Diagnos i s and Treatment (2006) (0)
Interferon: Does it still play a role? (2007) (0)
Neoplasms of the Neuroendocrine Pancreas: ACTH producing with Cushing syndrome (2017) (0)
Paraneoplastic Antigen Ma2 (PNMA2) Auto-Antibodies as Biomarkers for Early Small Intestine Neuroendocrine Tumors Detection (2010) (0)
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA biomarker (NETest) in the blood. (2020) (0)
Neuroendocrine tumours : Preface (2007) (0)
Neuroendocrine tumors - new perspection in their therapy. In: Advances in Pancreatic Disease (1999) (0)
Neuroendocrine Gut and Pancreatic Tumors Recent Advances in Diagnosis and Treatment a meeting held at Lofoten, Norway, June 24-28, 1992 (1993) (0)
Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) : A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS) (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kjell E. Öberg?

Kjell E. Öberg is affiliated with the following schools:

Uppsala University